SUMMARY One hundred and eighty-five patients with ulcerative colitis have been studied serially while receiving regular maintenance treatment with sulphasalazine (SASP) in a dose of 0.5 g four times daily. The circulating levels of the drug and its principal metabolites during remission do not influence the liability to relapse. When relapse does occur, the circulating level of sulphapyridine falls and remains depressed until remission occurs. This fall during a relapse is most pronounced when the patient suffers from universal colitis and is least marked in cases of distal colitis.
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Das et al. ' measured the serum concentration of sulphasalazine (SASP) and its metabolites in different phases of ulcerative colitis and showed that patients in remission had higher concentrations of total-sulphapyridine (total-SP) (>20 pg/ml) than those in relapse or those who failed to achieve remission (<20,g/ml). From these findings, they concluded that 'the most effective therapeutic concentration of total SP for the achievement of clinical remissions and not associated with sideeffects, lies within a range of 20 to 50 pzg/ml of serum.
The present study was designed to explore, first, whether the circulating concentrations of sulphasalazine and its metabolites in patients with ulcerative colitis during remission influence the liability to relapse, and secondly, what happens to the circulating concentrations in the event of a relapse.
Methods

PATIENTS
One hundred and eighty-five patients with ulcerative colitis, all of whom were receiving regular maintenance treatment with SASP in a dose of 0.5 g four times daily, were studied serially. The disease had been previously diagnosed on the basis of symptoms, sigmoidoscopic appearances, histology of the rectal mucosa, and the radiological appearances. Remission or relapse were defined on the Received for publication 4 March 1980 basis of the symptoms, the sigmoidoscopic appearances, and the histology of the rectal mucosa as graded by Truelove and Richards.2 Some clinical details of the patients are given in Table 1. The patients were treated during any relapses with oral and rectal prednisolone in addition to the SASP, which was continued in the same dosage during the whole period of the study. Some patients took tablets of diazepam, nitrazepam, iron, or vitamins in addition to the SASP.
Venous blood was collected at the outpatient department between 2 and 4.30p.m. Patients not taking SASP regularly were not included in the study. The blood samples were allowed to clot and the serum was separated. The serum samples were stored at -25°C until final biochemical analysis. The samples were analysed for concentrations of sulphasalazine (SASP), free-sulphapyridine (free-SP), N4-acetyl-sulphapyridine (AC-SP), sulphapyridine-O-glucuronide (SP-Gluc), N4-acetyl-sulphapyridine-O-glucuronide (AC-SP-Gluc), total-sulphapyridine (free-sulphapyridine and all its metabolites) (total-SP) and total-5-aminosalicylic acid (free-5-aminosalicylic acid+acetyl-5-aminosalicylic acid) (total-5-ASA).3-5 The biochemical estimation of the serum concentrations was done without knowledge of the clinical state of the patients.
The patients were followed for a period of one to three years. All the patients were seen repeatedly and hence blood samples were obtained on several occasions, in some patients as many as 12 times. The mean number of collections per patient was five. In addition to acetylation, SP also undergoes alculated and hydroxylation, the product of which in turn underd relapse.
goes glucuronidation. The hydroxylation of SP was variable in different subjects and it also varied in the same individual from time to time. The amount of hydroxylated SP (SP-Gluc+AC-SPvariations in Gluc) was significantly higher in the fast acetylators, of SASP and sufficiently so to cause the percentage of total rast, each in-hydroxylation to be higher in such subjects. This tnstant serum was mainly because of the significantly higher and AC-SP in concentrations of AC-SP-Gluc in the fast acetylators. condition re-Perhaps acetylation indirectly enhances hydroxythat he took lation. There was no significant difference in the ns within an serum concentrations of SASP in the fast and slow stable as SP L one patient Table 4 shows the relapse rate in three groups of patients. The first group was composed of patients all of whom during remission had a mean serum concentration of total-SP of less than 12 Fg/ml, the second of patients with a mean serum concentration of 12-20 ,ug/ml, and the third of patients with a mean serum concentration of more than 20 ,ug/ml. There was no significant difference in the relapse rate in these three groups, demonstrating that, when patients are maintained on the same dose of SASP, the circulating concentration of total-SP during remission does not influence the liability to relapse. In view of these findings, it is not surprising that the relapse rate was virtually identical in the fast and slow acetylaters, being 39% and 37% respectively.
The circulating level of SASP likewise does not influence the relapse rate in patients being maintained on a standard dose of the drug.
It is worth mentioning that these three groups of patients were comparable in respect of a number of important features, such as their age and sex composition, the length of history of ulcerative colitis, and the extent of colitis as judged radiologically. Table 5 shows that the ses.um concentration cf SASP did not significantly differ between remission and relapse in the same patient. On the other hand, serum concentrations of total-SP and of its two principal components-namely, free-SP and AC-SP-fell sharply during relapse. The greater the extent of the disease, the more marked was the fall. In Fig. 1 Nine of the patients with ulcerative colitis from the present study were subjected to panproctocolectomy because of failure to control their disease by medical treatment. Seven out of these nine had universal colitis and the other two had distal colitis. The seven patients with universal colitis had a mean serum total-SP concentration of 22.4 ,ug/ml during remission, while the mean level dropped below 7.5 t£g/ml during relapse. These patients then failed to improve clinically in spite of vigorous medical treatment and their serum SP concentration also failed to rise, though they continued on SASP in the same dosage as during remission. The colonic specimen removed at panproctocolectomy confirmed the presence of severe ulcerative colitis involving the whole of the colon. The other two patients with distal ulcerative colitis showed only a slight fall in the serum concentration of total-SP (during remission 28-8 ,ug/ml and during relapse 25.4 .tg/ml) and the resected specimen confirmed that the disease extended only up to the splenic flexure.
EFFECT OF RELAPSE ON CIRCULATING CONCENTRATIONS
Discussion
The serum concentrations of SP and its metabolites, and of 5-ASA, observed in the present study are comparable with those found by Das et Hydroxylation was unimodally distributed in this group of patients with ulcerative colitis and it ranged from 1 to 75%. The percentage of hydroxylation was higher in the fast acetylators than in the slow acetylators. This was mainly because of the higher serum concentration of AC-SP-Gluc in the former. It is probable that acetylated SP is hydroxylated more readily than free-SP.
The apparent discrepancy between the conclusions reached by Das et al.1 and those of the present study needs further discussion. Das et al. found that patients with ulcerative colitis during remission had higher concentrations of total-SP than those studied during relapse. In the latter group, 'coincidental with clinical improvement following an increase in the dose (of SASP), the serum total-SP concentration rose to within the range of patients responding earlier'. But this can be interpreted in at least two ways: (1) the low serum concentration of total-SP during remission made these patients liable to relapse; (2) the low serum SP concentration during relapse is an effect of the relapse.
The authors recognised both these possibilities but unfortunately chose the first one and, as a result, they advocated a dose of 3 g daily for regular maintenance therapy. The present study shows that the liability to relapse is not governed by the circulating levels during remission of SASP or of SP and its metabolites. This study also shows that, during relapse, the circulating concentrations of SP and its metabolites drop to lower levels, an observation which could explain the findings of Das et al. ' In fact, in their study they had seven patients whose serum concentration of total-SP was above 20 ,tg/ml, which they thought was the therapeutically effective serum concentration, but these patients were still in a relapse state. The fact that during relapse the serum concentration of SP and its metabolites drops to a lower level than during remission can be explained in at least two ways:
(1) during relapse there is intestinal hurry and hence there is no time to split SASP adequately or to absorb SP efficiently, or both; (2) inflamed colon may not be efficient in absorbing SP. During the present study, the patients observed no side-effects from the drug. This was partly because they had all been on SASP for some time before being included in the study and patients not able to tolerate 2 g SASP daily were not considered for the study. 
